265,217 Shares in Revvity Inc. $RVTY Purchased by Nuveen LLC

Nuveen LLC bought a new position in Revvity Inc. (NYSE:RVTY - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 265,217 shares of the company's stock, valued at approximately $28,060,000. Nuveen LLC owned approximately 0.23% of Revvity at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RVTY. Optiver Holding B.V. bought a new position in shares of Revvity during the 4th quarter valued at approximately $33,000. Quarry LP boosted its position in shares of Revvity by 45.7% during the 4th quarter. Quarry LP now owns 303 shares of the company's stock valued at $34,000 after acquiring an additional 95 shares during the last quarter. Vermillion Wealth Management Inc. bought a new position in shares of Revvity during the 4th quarter valued at approximately $41,000. New Age Alpha Advisors LLC bought a new position in shares of Revvity during the 1st quarter valued at approximately $44,000. Finally, Continuum Advisory LLC boosted its position in shares of Revvity by 39.3% during the 4th quarter. Continuum Advisory LLC now owns 471 shares of the company's stock valued at $53,000 after acquiring an additional 133 shares during the last quarter. 86.65% of the stock is owned by hedge funds and other institutional investors.

Revvity Stock Down 2.0%

NYSE:RVTY traded down $1.8350 during mid-day trading on Thursday, reaching $89.8650. The company's stock had a trading volume of 325,368 shares, compared to its average volume of 1,178,587. Revvity Inc. has a 1 year low of $85.12 and a 1 year high of $129.50. The stock has a fifty day moving average of $94.69 and a 200-day moving average of $99.49. The firm has a market capitalization of $10.43 billion, a PE ratio of 38.08, a price-to-earnings-growth ratio of 2.45 and a beta of 0.91. The company has a quick ratio of 2.75, a current ratio of 3.33 and a debt-to-equity ratio of 0.43.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings data on Monday, July 28th. The company reported $1.18 earnings per share for the quarter, beating analysts' consensus estimates of $1.14 by $0.04. Revvity had a return on equity of 7.66% and a net margin of 10.19%.The company had revenue of $720.28 million for the quarter, compared to the consensus estimate of $711.26 million. During the same quarter last year, the company earned $1.22 earnings per share. The firm's revenue for the quarter was up 4.1% compared to the same quarter last year. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. Equities research analysts forecast that Revvity Inc. will post 4.94 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 17th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Friday, October 17th. Revvity's dividend payout ratio (DPR) is currently 11.86%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on RVTY. The Goldman Sachs Group lowered their target price on Revvity from $140.00 to $125.00 and set a "buy" rating for the company in a research report on Tuesday, April 29th. Bank of America lowered their price target on Revvity from $116.00 to $110.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. UBS Group upgraded Revvity from a "neutral" rating to a "buy" rating and lowered their price target for the stock from $145.00 to $115.00 in a research report on Thursday, May 1st. Robert W. Baird lowered their price target on Revvity from $127.00 to $125.00 and set an "outperform" rating for the company in a research report on Tuesday, April 29th. Finally, JPMorgan Chase & Co. reduced their target price on Revvity from $120.00 to $100.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 29th. Ten equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $120.07.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.